scholarly journals Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years

2007 ◽  
Vol 156 (4) ◽  
pp. 425-430 ◽  
Author(s):  
Enrico Brignardello ◽  
Marco Gallo ◽  
Ileana Baldi ◽  
Nicola Palestini ◽  
Alessandro Piovesan ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Thyroid Carcinoma ◽  
Residual Disease ◽  
Malignant Tumors ◽  
Treatment Options ◽  
Distant Metastases ◽  
Anaplastic Thyroid Carcinoma ◽  
Adjuvant Chemoradiotherapy ◽  
Optimal Sequence ◽  
Hazard Ratios

Objective: Treatment options for anaplastic thyroid carcinoma (ATC), which is one of the most lethal human malignant tumors, include surgery, chemotherapy and radiotherapy usually combined in a multimodal approach, to improve survival and avoid death from local invasion. However, there is no standard protocol for ATC treatment and the optimal sequence within multimodal therapy is debated. We retrospectively report the clinical outcome of 30 ATC patients referred consecutively to the Oncological Endocrinology Unit of San Giovanni Battista Hospital (Turin, Italy) between 2000 and 2005. Design: Patients were treated by one of the following approaches: i) surgery followed by adjuvant-combined chemoradiotherapy; ii) neo-adjuvant chemoradiotherapy followed by surgery and adjuvant chemotherapy; or iii) chemotherapy alone. The surgical procedures were classified as ‘maximal debulking’ or ‘palliative resection’. Maximal debulking entailed total or near-total thyroidectomy and complete resection of all gross tumor or minimal residual disease adherent to vital structures, independently of the presence or absence of distant metastases. In palliative resections, macroscopic residual disease was left in the neck. Survival of patients stratified by treatment was assessed. Results: Analysis of multivariate hazard ratios showed that maximal debulking followed by adjuvant chemoradiotherapy was the only treatment that modified survival of ATC patients (hazard ratio= 0.23, 95% CI: 0.07–0.79), even if factors determining poor prognosis or increased surgical risk were present. Conclusions: Despite the overall grim outcome of ATC, these results justify an attempt at maximal debulking surgery, followed by adjuvant chemoradiotherapy, possibly in all ATC patients.

scholarly journals Combined chemotherapy and irradiation in anaplastic thyroid carcinoma

2003 ◽  
Vol 11 (3) ◽  
pp. 187-187
Author(s):  
Ivica Pejcic ◽  
Svetislav Vrbic ◽  
Mirjana Scekic
Keyword(s):  
Thyroid Carcinoma ◽  
Randomized Study ◽  
Distant Metastases ◽  
Complete Response ◽  
Anaplastic Thyroid Carcinoma ◽  
External Beam Radiation ◽  
Treatment Modalities ◽  
Combined Chemotherapy ◽  
Optimal Sequence ◽  
Beam Radiation

Background: Anaplastic thyroid carcinoma (ATC) is a very rare and extremely aggressive cancer; patient's death usually occurs rapidly after diagnosis with a mean survival of six months in the majority of individual research series. Treatment of ATC ranges from surgery, radiotherapy, chemotherapy, or a combination of these regimes. Yet, the optimal sequence of treatment modalities has not been established. Methods: From 1997 to 2002 six consecutive patients with a histological diagnosis of ATC were treated with combined chemotherapy and irradiation at our Clinic for Oncology, Clinical Center Ni?. Five of these patients were females and 1 male, aged between 28 and 71 years (mean age: 57 years). None of them had distant metastases at the time of diagnosis. Extrathyroidal extension was present in 3 patients with invasion into skin and hypoderm. Treatment consisted of doxorubicin 60 mg/m 2 plus cisplatin 60 mg/m 2 every three weeks. Total doses ranged between 158-375 mg/m 2 for doxorubicin and 183-380 mg/m 2 for cisplatin. External beam radiation to the neck was administered, at a daily dose of 1.2 Gy, up to total doses ranging between 45-60 Gy. Results: One patient achieved a complete response (CR) and one patient achieved a partial response (PR). Three patients had stable disease. One patient with CR progressed during follow-up and died 18 months from bone and brain metastases. The treatment was moderately well tolerated, although all patients experienced some mild form of toxicity; neutropenia occurred in all patients, but none of them required hospital admission. Median survival was 8 months (range: 4-18 months). Conclusion: We concluded that the present regimen produces meaningful responses for patients with localized ATC. A randomized study is needed to determine the effect on survival.

Anaplastic Thyroid Carcinoma with Rhabdomyoblastic Differentiation: A Case Report with a Good Clinical Outcome

2008 ◽  
Vol 19 (1) ◽  
pp. 62-65 ◽  
Author(s):  
Marijke Olthof ◽  
Adrienne C. M. Persoon ◽  
John T. M. Plukker ◽  
Jacqueline E. van der Wal ◽  
Thera P. Links
Keyword(s):  
Case Report ◽  
Clinical Outcome ◽  
Thyroid Carcinoma ◽  
Anaplastic Thyroid Carcinoma ◽  
Good Clinical Outcome

scholarly journals Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer

Cancers ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 1532 ◽  
Author(s):  
Malfitano ◽  
Somma ◽  
Prevete ◽  
Portella
Keyword(s):  
Thyroid Carcinoma ◽  
Therapeutic Potential ◽  
Checkpoint Inhibitors ◽  
Treatment Options ◽  
Differentiated Thyroid Carcinoma ◽  
Anaplastic Thyroid Carcinoma ◽  
Oncolytic Viruses ◽  
Cancer Models ◽  
Poorly Differentiated ◽  
Immunosuppressive Microenvironment

Virotherapy is a novel cancer treatment based on oncolytic viruses (OVs), which selectively infect and lyse cancer cells, without harming normal cells or tissues. Several viruses, either naturally occurring or developed through genetic engineering, are currently under investigation in clinical studies. Emerging reports suggesting the immune-stimulatory property of OVs against tumor cells further support the clinical use of OVs for the treatment of lesions lacking effective therapies. Poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC), have a poor prognosis and limited treatment options. Therefore, several groups investigated the therapeutic potential of OVs in PDTC/ATC models producing experimental data sustaining the potential clinical efficacy of OVs in these cancer models. Moreover, the presence of an immunosuppressive microenvironment further supports the potential use of OVs in ATC. In this review, we present the results of the studies evaluating the efficacy of OVs alone or in combination with other treatment options. In particular, their potential therapeutic combination with multiple kinases inhibitors (MKIs) or immune checkpoint inhibitors are discussed.

Does Surgery Improve the Survival of Patients with Advanced Anaplastic Thyroid Carcinoma?

1998 ◽  
Vol 118 (5) ◽  
pp. 728-731
Author(s):  
WEN-TSOUNG LU ◽  
Jen-Der Lin ◽  
Hong-So Huang ◽  
Tzu-Chieh Chao
Keyword(s):  
Thyroid Carcinoma ◽  
Distant Metastases ◽  
Anaplastic Thyroid Carcinoma ◽  
Disease Group ◽  
Localized Disease ◽  
The Mean ◽  
Group 2 ◽  
Nonsurgical Patients ◽  
Head Neck ◽  
Group 1

Anaplastic thyroid carcinoma is one of the most lethal neoplasms, with poor prognosis being reported by most authors. The benefits of surgery for most cases of advanced disease remain controversial. In this study we asked the following question: Does surgical intervention alter outcomes for patients with advanced anaplastic thyroid carcinoma? Forty-six patients with advanced anaplastic thyroid carcinoma were analyzed. There were 20 patients with advanced localized disease (group 1), 15 of whom received surgery. Of the other 26 patients with evidence of distant metastases (group 2), 13 received surgery. For group 1 patients, the mean survival was 12.8 months versus 8.6 months in the surgical and nonsurgical subgroups ( p = 0.46). For group 2 patients, the mean survival was 3.5 months versus 2.8 months in the surgical and nonsurgical subgroups ( p = 0.72). These data suggest that surgery does not improve survival for patients with advanced anaplastic thyroid carcinoma. In conclusion, the mean survival showed no significant differences between surgical and nonsurgical patients ( p = 0.43). This study suggests that surgical resection does not improve the survival of patients with advanced anaplastic thyroid carcinoma. (Otolaryngol Head Neck Surg 1998;118:728–31.)

scholarly journals Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens

Cancer ◽  
2006 ◽  
Vol 107 (8) ◽  
pp. 1786-1792 ◽  
Author(s):  
Yongjin Wang ◽  
Richard Tsang ◽  
Sylvia Asa ◽  
Brendan Dickson ◽  
Tamara Arenovich ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Thyroid Carcinoma ◽  
Anaplastic Thyroid Carcinoma

scholarly journals Lenvatinib in Anaplastic Thyroid Carcinoma (ATC) in a Tertiary Caner Hospital- a Single Institute Experience

2021 ◽  
pp. 7-10
Author(s):  
Rakesh Sharma ◽  
P. S. Dattatreya ◽  
A. V. S. Suresh ◽  
Ch Mohana Vamsy
Keyword(s):  
Thyroid Carcinoma ◽  
Side Effect ◽  
Case Reports ◽  
Treatment Options ◽  
Anaplastic Thyroid Carcinoma ◽  
Common Side Effect ◽  
Good Clinical Response ◽  
Rare Form ◽  
Short Survival ◽  
Effective Option

Anaplastic Thyroid Carcinoma (ATC) is an aggressive rare form of caner with limited treatment options and short survival. In view of initial case reports have shown some good clinical response with lenvatinib, we used the same in our institute. We are presenting a retrospective series of 4 cases between 2018-2021. It showed very promising results with 75% showing clinically meaningful regression of tumor. Hypertension is the most common side effect, which should be aggressively managed. We feel that, lenvatinib remains a safe and effective option to explore in patients with refractory anaplastic thyroid carcinoma.

Metastatic follicular thyroid carcinoma to the paranasal sinuses: a case report and review

1997 ◽  
Vol 111 (7) ◽  
pp. 647-651 ◽  
Author(s):  
Ken W. Altman ◽  
Natasha Mirza ◽  
Lucien Philippe
Keyword(s):  
Thyroid Carcinoma ◽  
Paranasal Sinuses ◽  
Poor Prognosis ◽  
Follicular Thyroid Carcinoma ◽  
Treatment Options ◽  
Distant Metastases ◽  
Differentiated Thyroid Carcinoma ◽  
Endoscopic Biopsy ◽  
Primary Lesion ◽  
Ethmoid Sinuses

AbstractThyroid carcinoma metastatic to the paranasal sinuses is extremely rare, with only 11 cases reported in the English and European literature. We report a case of metastatic follicular thyroid carcinoma to the clivus with extension into the sphenoid and posterior ethmoid sinuses. Pathological diagnosis was obtained using an intranasal endoscopic biopsy. As with our patient, metastatic thyroid carcinoma may present with symptoms related to distant metastases rather than the primary lesion. Distant metastases in differentiated thyroid carcinoma portends a poor prognosis. Our case of metastatic thyroid carcinoma to the paranasal sinuses is summarized in the context of the 11 additional cases, and treatment options are discussed.

scholarly journals PD-1 Blockade in Anaplastic Thyroid Carcinoma

2020 ◽  
Vol 38 (23) ◽  
pp. 2620-2627 ◽  
Author(s):  
Jaume Capdevila ◽  
Lori J. Wirth ◽  
Thomas Ernst ◽  
Santiago Ponce Aix ◽  
Chia-Chi Lin ◽  
...  
Keyword(s):  
Adverse Events ◽  
Thyroid Carcinoma ◽  
Overall Response Rate ◽  
Response Rate ◽  
Treatment Options ◽  
Locally Advanced ◽  
Complete Response ◽  
Anaplastic Thyroid Carcinoma ◽  
Overall Response ◽  
Humanized Monoclonal Antibody

PURPOSE Anaplastic thyroid carcinoma is an aggressive malignancy that is almost always fatal and lacks effective systemic treatment options for patients with BRAF-wild type disease. As part of a phase I/II study in patients with advanced/metastatic solid tumors, patients with anaplastic thyroid carcinoma were treated with spartalizumab, a humanized monoclonal antibody against the programmed death-1 (PD-1) receptor. METHODS We enrolled patients with locally advanced and/or metastatic anaplastic thyroid carcinoma in a phase II cohort of the study. Patients received 400 mg spartalizumab intravenously, once every 4 weeks. The overall response rate was determined according to RECIST v1.1. RESULTS Forty-two patients were enrolled. Adverse events were consistent with those previously observed with PD-1 blockade. Most common treatment-related adverse events were diarrhea (12%), pruritus (12%), fatigue (7%), and pyrexia (7%). The overall response rate was 19%, including three patients with a complete response and five with a partial response. Most patients had baseline tumor biopsies positive for PD-L1 expression (n = 28/40 evaluable), and response rates were higher in PD-L1–positive (8/28; 29%) versus PD-L1–negative (0/12; 0%) patients. The highest rate of response was observed in the subset of patients with PD-L1 ≥ 50% (6/17; 35%). Responses were seen in both BRAF-nonmutant and BRAF-mutant patients and were durable, with a 1-year survival of 52.1% in the PD-L1–positive population. CONCLUSION To our knowledge, this is the first clinical trial to show responsiveness of anaplastic thyroid carcinoma to PD-1 blockade.

Sign in / Sign up

Export Citation Format

Share Document